Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 17/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15467492 | 1.00 | MME (0.44) | MMESYKATMMMEL1ACE | |
| SCHEMBL19407212 | 0.93 | SYK (0.40) | MMESYKMMEL1ACE | |
| SCHEMBL22018890 | 0.93 | SYK (0.40) | MMESYKMMEL1ACE | |
| SCHEMBL21350802 | 0.93 | MME (0.43) | MMESYKATMMMEL1ACE | |
| SCHEMBL26378137 | 0.92 | MME (0.44) | MMESYKATMMMEL1ACE | |
| SCHEMBL15474308 | 0.92 | MME (0.46) | MMEMMEL1ACE | |
| SCHEMBL19687831 | 0.92 | MME (0.46) | MMEMMEL1ACE | |
| SCHEMBL19705794 | 0.91 | MME (0.50) | MMESYKATMMMEL1ACE | |
| SCHEMBL17968662 | 0.91 | MME (0.50) | MMESYKATMMMEL1ACE | |
| SCHEMBL19771839 | 0.90 | MME (0.45) | MMESYKATMMMEL1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-11230536-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-01-25 | — | — | US | disclosed |
| US-11124502-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210061776-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200283422-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-10752599-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-25 | — | — | US | disclosed |
| US-9873685-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170349574-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230536-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | MME, CTSC, REN | MME 1/4885SYK 3066/4885ATM 4884/4885 |
| US-20200283422-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885SYK 3372/4885ATM 4854/4885 |
| US-10752599-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | MME, CTSC, REN | MME 1/4885SYK 3066/4885ATM 4884/4885 |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885SYK 3372/4885ATM 4854/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885SYK 3372/4885ATM 4854/4885 |
| US-11124502-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885SYK 3372/4885ATM 4854/4885 |
| US-20170349574-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885SYK 3372/4885ATM 4854/4885 |
| US-20210061776-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | MME 1/4885SYK 3168/4885ATM 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.